Your Medications Aren't Working. Your Genes May Be Why.

CYP2D6 is one of your liver’s most important drug-metabolizing enzymes. It breaks down a quarter of all medications used clinically, including antidepressants, opioids, beta-blockers, and many others. If CYP2D6 is working normally, it clears these drugs at the right pace, delivering therapeutic benefit without accumulation.

Here’s the problem: roughly 7-10% of people of European ancestry carry variants that slow CYP2D6 to a crawl, while others carry gene duplications that speed it up dramatically. Poor metabolizers, who carry the *2 or *4 variants, cannot break down these drugs efficiently. A standard dose of an antidepressant or opioid can accumulate to toxic levels in your bloodstream, causing severe side effects at doses that should be therapeutic.

If you’re a poor metabolizer, you might experience dizziness, brain fog, nausea, or tremors on antidepressants at doses that work fine for others. On opioids, you might feel dangerously sedated. On beta-blockers, your heart rate might drop too low. Standard dosing was never designed for your genetics.

CYP2C19 breaks down a large class of antidepressants (SSRIs like sertraline and escitalopram), the blood thinner clopidogrel (Plavix), and proton pump inhibitors used for acid reflux. For antidepressants, slow metabolism means higher blood levels and potentially stronger side effects before you find a therapeutic dose. For clopidogrel, the situation is more serious.

Clopidogrel is a prodrug, meaning your body has to activate it to work. If you’re a poor metabolizer carrying the *2 or *3 variant, roughly 2-15% of people depending on ancestry, your body cannot activate clopidogrel efficiently. You may take the medication faithfully, believing you’re protected from blood clots after a stent, when your body is barely activating any of it.

For antidepressants, poor metabolism can feel like the medication is working too well, leaving you groggy or emotionally flattened. For clopidogrel, you feel nothing because nothing is happening. The drug sits in your bloodstream doing nothing, while you think you’re protected from another cardiac event. This is particularly dangerous because the failure is silent.

CYP2C9 metabolizes warfarin, the most commonly prescribed anticoagulant for atrial fibrillation and clotting disorders. It also breaks down NSAIDs like ibuprofen and naproxen, and statins. Warfarin has one of the narrowest therapeutic windows in medicine, meaning the difference between an effective dose and a dangerous one is small. Your CYP2C9 genetics directly control this window.

Roughly 5-10% of people of European ancestry carry slow variants (*2 or *3) of CYP2C9. Poor metabolizers require significantly lower warfarin doses to achieve the same anticoagulation as people with normal variants, and standard dosing can cause dangerous bleeding. The FDA now recommends genetic testing before warfarin initiation specifically because of CYP2C9 variants.

On a standard warfarin dose, a poor metabolizer might bleed from the gums, develop bruises from minor bumps, or worse, internal bleeding. You follow your doctor’s instructions exactly, get your INR checked, and still end up in the emergency room. Your doctor adjusts the dose, but without knowing your genetics, it’s guesswork. With CYP2C9 testing, the right dose is known from day one.

VKORC1 encodes vitamin K epoxide reductase, the protein that warfarin actually targets to thin your blood. Your VKORC1 genetics don’t affect how fast you metabolize warfarin; instead, they control how sensitive your clotting system is to warfarin’s effects. The -1639G>A variant is common, with the A allele carried by roughly 40% of people of European ancestry.

If you carry the A allele, your VKORC1 protein is inherently more sensitive to warfarin’s effects. You need a substantially lower warfarin dose than someone with the GG genotype to achieve the same degree of blood thinning. The standard warfarin dose works because it’s designed for an average population, but average doesn’t apply to you.

On standard warfarin dosing, VKORC1 A carriers find themselves over-anticoagulated, with bleeding risk even at doses that feel conservative. You might be told your INR is too high and your dose is cut, then a few weeks later it’s too low. Without knowing your VKORC1 status, your warfarin management becomes a guessing game of constant adjustments.

SLCO1B1 encodes a transporter protein that moves statins from your bloodstream into your liver cells, where they lower cholesterol. If this transporter works normally, the right amount of statin gets where it needs to be. If the transporter is impaired, statins accumulate in your bloodstream instead of your liver, raising your systemic exposure and your risk of side effects.

The *5 variant (rs4149056), carried by roughly 15% of people, reduces this transporter’s function. People with SLCO1B1 *5 variants experience significantly higher statin levels in their blood on standard doses, dramatically increasing their risk of muscle pain and myopathy. This is especially true with simvastatin, the most commonly prescribed statin.

You start simvastatin at the standard dose to lower your cholesterol. Within weeks, your muscles start aching. Your doctor assumes it’s exercise or age. You push through. The pain gets worse. You stop the statin, and the pain slowly fades. You assume you’re statin-intolerant and never try again. But you’re not intolerant; you have a genetic variant that makes standard dosing dangerous for you.

TPMT metabolizes thiopurine drugs including azathioprine (used for autoimmune diseases like lupus and Crohn’s disease) and 6-mercaptopurine (used in acute lymphoblastic leukemia). If TPMT is working normally, it breaks down these drugs at a safe pace. If it’s impaired, toxic metabolites accumulate in your bone marrow, destroying blood cells.

Roughly 0.3% of people are completely deficient in TPMT, while another 10-15% are intermediate metabolizers. TPMT-deficient patients who receive standard thiopurine doses face severe bone marrow suppression, potentially fatal infections from wiped-out white blood cells, and severe anemia. This is so serious that TPMT testing is now recommended before starting thiopurines.

A patient starts azathioprine for Crohn’s disease at standard dosing. Two weeks later, they develop a severe infection from a white blood cell count that has collapsed. They’re admitted to the hospital. The drug is stopped. TPMT testing is finally done, and it shows they’re a poor metabolizer. The medication was never wrong; the dose was lethal for their genetics. With testing upfront, a safe dose would have been given from the start.